7.92 USD
▲+0.22+8.64%
盘后 7.29 0.00%
2026-08-03
市值
$607.31M
市盈率
—
EPS
-0.59
股息率
—
52 周区间
0.71 – 8.33
成交量
1.45M
Beta
1.11
目标价
14.38
52W 低 0.7152W 高 8.33
价格走势
公司简介
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical...